SUPN (Supernus Pharmaceuticals Inc.) stock: $42.00, $2.44B market cap, $372.1M cash, $2.07B EV, $2.75B fully diluted market cap. Next expected readout: Dec-26. Lead program: apomorphine infusion (Idiopathic Parkinson's Disease), Phase 3. Data from Fully Diluted's biotech stocks database.
Enterprise value
$2,069.2M
Balance sheet
| Cash | $372.1M |
|---|
| Debt | $0.0M |
|---|
| Net cash | $372.1M |
|---|
| Enterprise value | $2,069.2M |
|---|
| Basic shares | 58.2M shares |
|---|
| Fully diluted shares | 65.4M shares |
|---|
| Fully diluted market cap | $2,746.6M |
|---|
| Cash per share | $6.39 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading SUPN daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Oct 13 - Nov 24 | SPN-812 | Phase 3 | Attention-Deficit/Hyperactivity Disorder | — |
| Feb 10 - Mar 24 | BIS-001ER | Phase 2 | Focal Impaired Awareness Seizures | — |
| Feb 11 - Mar 25 | SPN-821 2400 mg | Phase 2 | Major Depressive Disorder (MDD) | — |
| Sep 12 - Oct 24 | SPN-817 | Phase 2 | Focal Onset Seizures | — |
| Feb 11 - Mar 24 | SPN-817 | Phase 2 | Epilepsy; Seizures, Epileptic | — |
| Feb 11 - Mar 24 | SPN-817 | Phase 2 | Focal Onset Seizures | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
Qelbree
Approved · Active
Target Norepinephrine/serotonin modulator (viloxazine)
Indications- Attention deficit hyperactivity disorder (ADHD) (Approved)
Status note One of nine commercial products marketed in the U.S. Indication not stated in the excerpts.
GOCOVRI
Approved · Active
Target NMDA receptor (amantadine)
Indications- Parkinson's disease dyskinesia (Approved)
Status note One of nine commercial products marketed in the U.S. Generic competition permitted beginning June 2029 (or sooner under certain conditions) under settlement agreements. Indication not stated in the excerpts.
Oxtellar XR
Approved · Active
Target Voltage-gated sodium channels (oxcarbazepine)
Indications- Partial-onset seizures (epilepsy) (Approved)
Status note One of nine commercial products marketed in the U.S. Indication not stated in the excerpts.
Trokendi XR
Approved · Active
Target Sodium channels / GABA / glutamate (topiramate)
Indications- Epilepsy (partial-onset; primary generalized tonic-clonic seizures) (Approved)
- Migraine prophylaxis (Approved)
Status note One of nine commercial products marketed in the U.S. Indication not stated in the excerpts.
APOKYN
Approved · Active
Target Dopamine receptors (apomorphine)
Indications- Parkinson's disease OFF episodes (acute intermittent treatment) (Approved)
Status note One of nine commercial products marketed in the U.S. Company recognized $54.9M impairment charges on the APOKYN acquired intangible asset in Q2 2026. Indication not stated in the excerpts.
XADAGO
Approved · Active
Target MAO-B
Indications- Parkinson's disease (adjunctive to levodopa/carbidopa) (Approved)
Status note One of nine commercial products marketed in the U.S. Indication not stated in the excerpts.
MYOBLOC
Approved · Active
Target SNARE proteins (botulinum toxin type B)
Indications- Cervical dystonia (Approved)
- Chronic sialorrhea (Approved)
Status note One of nine commercial products marketed in the U.S. Indication not stated in the excerpts.
ONAPGO
Approved · Active
Aliases SPN-830
Target Dopamine receptors (apomorphine)
Indications- Parkinson's disease motor fluctuations (subcutaneous infusion) (Approved)
Status note One of nine commercial products marketed in the U.S. FDA approved February 2025; acquired in-process R&D considered complete at approval. Supplier constraints impacted ability to meet demand (announced November 4, 2025). Indication not stated in the excerpts.
ZURZUVAE
Approved · Active Modality: small molecule
Aliases Zuranolone, SAGE-217
Target GABAA
Partnerships Biogen: co-commercialization of ZURZUVAE in the U.S. (co-exclusive license for SAGE-217 products; Biogen is principal in customer sales; costs shared equally); Shionogi: collaboration for zuranolone in MDD and other indications (Shionogi responsible for clinical development and regulatory filings; royalties and milestones to Supernus); acquired via Sage Therapeutics acquisition (closed July 31, 2025)
Indications- Postpartum depression (PPD) (Approved)
Status note Approved for the treatment of PPD in the U.S.; marketed in the U.S. Company generated $63.0M collaboration revenue (ZURZUVAE) in H1 2026. $20M licensing revenue recognized in H1 2026 on a commercial milestone under the Shionogi collaboration.
SPN-817
Stage not disclosed · Active
Target acetylcholinesterase
Indications- Focal Onset Seizures (Phase 2)
- Epilepsy (Phase 2)
- Seizures, Epileptic (Phase 2)
Status note Named product candidate with direct R&D program expenses; no indication, stage, modality, or target disclosed in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.